Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically confirmed non-small cell lung cancer (NSCLC) which is accessible to biopsy.~* Patient must have ECOG Performance Status of 0, 1, or 2.~* Life expectancy greater than 12 weeks.~* Patient must have adequate bone marrow, renal and hepatic function as defined in the protocol.~* Completed all prior therapy at least 3 weeks prior to registration and be adequately recovered from that therapy.~* Must be at least 18 years of age.~* Meet pre-entry requirements as specified in Section 7.0.~* Female patients of child-bearing potential must have a negative serum pregnancy test prior to study entry.~* Patients of child-bearing potential must agree to use an effective form of contraception while on study and for 3 months following completion of study treatment.~* Patient must not have more than one prior chemotherapy regimen.~* Final eligibility for a clinical trial is determined by the health professionals conducting the trial.~Exclusion Criteria:~* Chronic treatment with systemic steroids or other immunosuppressive agents.~* Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases.~* A known history of HIV seropositivity.~* Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).~* Patients with an active, bleeding diathesis or an oral anti-vitamin K medication (except low dose coumadin).~* Known hypersensitivity to everolimus, sirolimus, or any of its excipients.~* Patient is pregnant or breast-feeding.~* Patient has intercurrent illness including, but not limited to: ongoing active or severe infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension, myocardial infarction within 6 months, uncontrolled diabetes mellitus, chronic liver or renal disease, active upper GI tract ulceration or psychiatric illness/social situations that would limit compliance with study requirements.~* Patient is unable to swallow RAD001.~* History of other invasive malignancies, with the exception of non-melanoma skin cancer, if there is any evidence of the malignancy being present within the past 5 years.~* History of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80. Symptoms may include any reaction such as bronchospasm, generalized urticaria, systolic BP ≤ 80mm Hg, and angioedema.~* Patient has received treatment with an investigational agent within 4 weeks of registration.~* Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RAD001+Docetaxel (Type: EXPERIMENTAL): RAD001 in combination with Docetaxel.

Based on this trial design, predict the completion outcome and termination type (if applicable).